We talk to the new CEO of CEE group Penta Hospitals International (PHI). Martin Hrezo discusses current markets Poland, Slovakia and Czechia, the synergies between them and why it decided to slow down its international expansion.
We talk to Dr Lajos Fabian, chairman of MedAlliance Holding, a grouping of seven investors which has been busy buying healthcare providers in the fragmented Hungarian healthcare market through its buy-and-build platform Tritonlife, which it launched in late 2018. The aim is to replicate the achievements of Medigroup in Serbia and Regina Maria in Romania with eventual sale or IPO, but not for at least 5-7 years.
HBI hears that an upcoming bill will raise the barriers to entry in dentistry for private equity investors while leaving the rest of outpatient untouched.
Two of Europe’s biggest healthcare companies which were widely expected to IPO imminently are now, we hear, ruling out this year. Why the delay – and what does this tell us about the state of a slowing market? HBI speaks to an operator CEO and investment banking sources.
Europe's largest telemedicine provider has become the first to enter the German market by taking a JV with the country's fourth-largest hospital group.
Listed Romanian healthcare group Medlife is looking to neighbouring countries for expansion, says its CEO. We analyse the opportunity in the four that he singled out, each of which is ripe for consolidation.
The most successful health care entrepreneur in central and eastern Europe has died aged just 65. What was this formidable man like and what does this mean for his many ventures?
PharmAccess Foundation, the pioneering Dutch NGO which has lent money to 1,000 for-profit clinics across Africa and launched an innovative mobile health payment scheme in Kenya is now working closely with governments.
Private equity giant TPG Capital has reportedly entered exclusive negotiations to take over the management of Abraaj's $1bn healthcare fund which has assets in Kenya, Nigeria, Pakistan and India. It looks to be the end of a protracted saga which contacts say might dampen fund managers' appetite for so-called impact investing in emerging markets.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.